Serum levels of rapid turnover proteins are decreased and related to systemic inflammation in patients with ovarian cancer

Watanabe,Takafumi; Shibata,Masahiko; Nishiyama,Hiroshi; Soeda,Shu; Furukawa,Shigenori; Gonda,Kenji; Takenoshita,Seiichi; Fujimori,Keiya

doi:10.3892/ol.2013.1735

Serum levels of rapid turnover proteins are decreased and related to systemic inflammation in patients with ovarian cancer

Authors:
- Takafumi Watanabe
- Masahiko Shibata
- Hiroshi Nishiyama
- Shu Soeda
- Shigenori Furukawa
- Kenji Gonda
- Seiichi Takenoshita
- Keiya Fujimori
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Fukushima Medical University, Fukushima, Fukushima 960‑1295, Japan, Department of Gastrointestinal Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama 350‑1298, Japan, Department of Organ Regulatory Surgery, Fukushima Medical University, Fukushima, Fukushima 960‑1295, Japan
Published online on: December 6, 2013 https://doi.org/10.3892/ol.2013.1735
Pages: 373-377

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Poor nutritional status is common in ovarian cancer. It is well known that the nutritional status of a patient with malignant disease is associated with survival, and that it can be assessed by serum levels of rapid turnover proteins (RTPs), such as retinol binding protein, prealbumin and transferrin. Systemic inflammation, usually observed in the form of elevated C‑reactive protein (CRP) or neutrophil/lymphocyte ratio (NLR), occurs by various mechanisms involving numerous pro‑inflammatory cytokines. These include interleukin (IL)‑17 and other soluble protein mediators, such as soluble IL‑2 receptor (sIL‑2R) and vascular endothelial growth factor (VEGF). In this study, circulating levels of RTP were decreased in advanced stages of ovarian cancer, and significant inverse correlations were found between RTP levels and serum levels of CRP or NLR. CRP levels were also correlated with serum levels of VEGF and sIL‑2R. Moreover, NLR, VEGF and sIL‑2R levels, and IL‑17 production, were all inversely correlated with RTP levels. These findings indicate that chronic inflammation may be associated with compromised immune function, such as an impaired T‑cell response, via various inflammatory proteins, including sIL‑2R, VEGF and IL‑17. The key mechanisms leading to cancer cachexia, in which nutritional impairment is a major clinical issue, appear to be primarily immune reactions caused by chronic inflammation. Anti‑inflammatory treatments may be effective in clinically improving various symptoms associated with these mechanisms.

View Figures

View References

1	Ministry of Health, Labour and Welfare. Annual Health, Labour and Welfare Report 2011–2012. http://www.mhlw.go.jp/toukei/. Accessed September 6, 2012
2	Asher V, Lee J and Bali A: Preoperative serum albumin is an independent prognostic predictor of survival in ovarian cancer. Med Oncol. 29:2005–2009. 2012. View Article : Google Scholar : PubMed/NCBI
3	Blackburn GL, Bistrian BR, Maini BS, Schlamm HT and Smith MF: Nutritional and metabolic assessment of the hospitalized patient. J Parenter Enteral Nutr. 1:11–22. 1977. View Article : Google Scholar : PubMed/NCBI
4	Inoue Y, Nezu R, Matsuda H, Takagi Y and Okada A: Rapid turnover proteins as a prognostic indicator in cancer patients. Surg Today. 25:498–506. 1995. View Article : Google Scholar : PubMed/NCBI
5	Valandingham S, Spiekerman AM and Newmark SR: Prealbumin: a parameter of visceral protein levels during albumin infusion. J Parenter Enteral Nutr. 6:230–231. 1982. View Article : Google Scholar : PubMed/NCBI
6	Delpeuch F, Cornu A and Chevalier P: The effect of iron-deficiency anaemia on two indices of nutritional status, prealbumin and transferrin. Br J Nutr. 43:375–379. 1980. View Article : Google Scholar : PubMed/NCBI
7	Mears E: Outcome of continuous process improvement of a nutritional care program incorporating serum prealbumin measurements. Nutrition. 12:479–484. 1996. View Article : Google Scholar
8	McMillan DC, Canna K and McArdle CS: Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg. 90:215–219. 2003. View Article : Google Scholar
9	Pierce BL, Ballard-Barbash R, Bernstein L, Baumgartner RN, Neuhouser ML, Wener MH, Baumgartner KB, Gilliland FD, Sorensen BE, McTiernan A and Ulrich CM: Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol. 27:3437–3444. 2009. View Article : Google Scholar
10	Kodama J, Miyagi Y, Seki N, Tokumo K, Yoshinouchi M, Kobashi Y, Okuda H and Kudo T: Serum C-reactive protein as a prognostic factor in patients with epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 82:107–110. 1999. View Article : Google Scholar : PubMed/NCBI
11	Witkowska AM: On the role of sIL-2R measurements in rheumatoid arthritis and cancers. Mediators Inflamm. 3:121–130. 2005. View Article : Google Scholar : PubMed/NCBI
12	Gonda K, Shibata M, Shimura T, Machida T, Suzuki S, Nakamura I, Ohki S, Sakurai K, Ohto H, Tomira R and Takenoshita S: Serum soluble interleukin-2 receptor is increased in malnourished and immunosuppressed patients with gastric and colorectal cancer: Possible influence of myeloid-derived suppressor cells. World J Oncol. 3:158–164. 2012.
13	Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q and Dong C: A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 6:1133–1141. 2005. View Article : Google Scholar : PubMed/NCBI
14	Chen Z, Tato CM, Muul L, Laurence A and O’Shea JJ: Distinct regulation of interleukin-17 in human T helper lymphocytes. Arthritis Rheum. 56:2936–2946. 2007. View Article : Google Scholar : PubMed/NCBI
15	Santarlasci V, Maggi L, Capone M, Frosali F, Querci V, De Palma R, Liotta F, Cosmi L, Maggi E, Romagnani S and Annunziato F: TGF-beta indirectly favors the development of Th17 cells by inhibiting Th1 cells. Eur J Immunol. 39:207–215. 2009. View Article : Google Scholar : PubMed/NCBI
16	Kolls JK and Lindén A: Interleukin-17 family members and inflammation. Immunity. 21:467–476. 2004. View Article : Google Scholar : PubMed/NCBI
17	Yazawa T, Shibata M, Gonda K, Machida T, Suzuki S, Kenjo A, Nakamura I, Tsuchiya T, Koyama Y, Sakurai K, et al: Increased IL-17 production correlates with both immunosuppression involving MDSC and nutritional impairment in patients with various gastrointestinal cancers. Mol Clin Oncol. 1:675–679. 2013.
18	Watanabe T, Shibata M, Nishiyama H, Soeda S, Furukawa S, Gonda K, Takenoshita S and Fujimori K: Elevated serum levels of vascular endothelial growth factor is effective as a marker for malnutrition and inflammation in patients with ovarian cancer. Biomed Rep. 1:197–201. 2013.PubMed/NCBI
19	Goldmann E: The growth of malignant disease in man and the lower animals, with special reference to the vascular system. Proc R Soc Med. 1:1–13. 1908.PubMed/NCBI
20	Rubin H: Cancer cachexia: its correlations and causes. Proc Natl Acad Sci USA. 100:5384–5389. 2003. View Article : Google Scholar : PubMed/NCBI
21	Deans C and Wigmore SJ: Systemic inflammation, cachexia and prognosis in patients with cancer. Curr Opin Clin Nutr Metab Care. 8:265–269. 2005. View Article : Google Scholar : PubMed/NCBI
22	Mantovani G, Macciò A, Madeddu C, Serpe R, Antoni G, Massa E, Dessì M and Panzone F: Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia. J Mol Med (Berl). 88:85–92. 2010. View Article : Google Scholar : PubMed/NCBI
23	Fearon KC, Von Meyenfeldt MF, Moses AG, Van Geenen R, Roy A, Gouma DJ, Giacosa A, Van Gossum A, Bauer J, Barber MD, et al: Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut. 52:1479–1486. 2003. View Article : Google Scholar